New & Noteworthy

Feb 02, 2018
Pharmaceutical Executive
2017 was a year of swings and momentum for the pharma and biotech markets. Is more stable footing ahead? Peter Young reports.
Feb 01, 2018
In his State-of-the-Union address this week, President Trump continued his harangue about unfair drug prices in the U.S., but he surprised many observers by failing to call for full repeal of the Affordable Care Act.
Jan 31, 2018
Pharmaceutical Executive
Molly Harper, vice president of commercial development at Akcea Therapeutics, outlines best practices for this unique group of therapies
Jan 30, 2018
Improving the productivity of sponsors’ clinical development processes will continue to be a primary driver of outsourcing in 2018, writes Nuala Murphy.
Jan 30, 2018
As the Ukranian healthcare market opens up to more public and private competition, it will become more attractive for investors — both Ukrainian and foreign, write Lana Sinichkina and Anna Zorya.
Jan 29, 2018
Outlining the procedures to manage anti-corruption risk that life sciences companies should consider before doing business in China.
Jan 26, 2018
Pharmaceutical Executive
In our annual temperature check on the life sciences sector and its outlook for the months ahead, we explore eight trends that will shape the biopharma industry landscape in 2018.
Jan 18, 2018
Rachel Howard makes the case for pharmaceutical companies to include the developing world front and centre in their vision.
Jan 12, 2018
Pharmaceutical Executive
Bruno Strigini, CEO of Novartis Oncology, talks about the company’s pioneering path in cancer and the related broader issues such as pricing and value and new innovations in cancer science.
Jan 11, 2018
mHealth devices and apps that continuously monitor patient symptoms and help with adherence also are likely to reshape medical practice – and with it the products pharma produce, writes Vicki Anastasi.
native1_300x100
lorem ipsum